Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Q3 2025 value amounting to $20.9 million.

  • Viridian Therapeutics, Inc.\DE's Non-Current Debt rose 178.82% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 178.82%. This contributed to the annual value of $20.6 million for FY2024, which is 186.59% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Non-Current Debt stood at $20.9 million for Q3 2025, which was up 178.82% from $12.4 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Non-Current Debt registered a high of $20.9 million during Q3 2025, and its lowest value of $12.4 million during Q2 2025.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Non-Current Debt averaged around $19.0 million, with its median value being $20.5 million (2024).
  • Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 186.59% in 2024, then crashed by 2935.9% in 2025.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's Non-Current Debt (Quarter) stood at $20.2 million in 2023, then increased by 1.87% to $20.6 million in 2024, then rose by 1.5% to $20.9 million in 2025.
  • Its Non-Current Debt stands at $20.9 million for Q3 2025, versus $12.4 million for Q2 2025 and $20.7 million for Q1 2025.